CCDC15

Summary

CCDC15 (coiled-coil domain containing 15, HGNC:25798) is a protein-coding gene on chromosome 11q24.2, encoding Coiled-coil domain-containing protein 15 (Q0P6D6). Plays an important role in primary cilium assembly, maintenance, and length regulation.

Involved in cilium assembly and positive regulation of centriole elongation. Located in centriole and centrosome.

Source: NCBI Gene 80071 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 157 total — 3 pathogenic
• MANE Select transcript: NM_025004

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25798
Approved symbol	CCDC15
Name	coiled-coil domain containing 15
Location	11q24.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13215
Ensembl gene	ENSG00000149548
Ensembl biotype	protein_coding
OMIM	621146
Entrez	80071

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000344762, ENST00000524471, ENST00000529051, ENST00000530061, ENST00000892371, ENST00000921761, ENST00000921762, ENST00000921763, ENST00000921764, ENST00000921765

RefSeq mRNA: 1 — MANE Select: NM_025004 NM_025004

CCDS: CCDS44756

Canonical transcript exons

ENST00000344762 — 16 exons

Exon	Start	End
ENSE00000991211	124954724	124954909
ENSE00000991212	124959115	124959264
ENSE00000991213	124959815	124960003
ENSE00000991214	124975096	124975209
ENSE00000991215	124977478	124977600
ENSE00000991216	124986742	124986888
ENSE00000991218	124991461	124991583
ENSE00001325847	125005109	125005212
ENSE00001374710	124992580	124992687
ENSE00001376326	124993169	124993243
ENSE00001428014	124987127	124988134
ENSE00001506001	125003867	125003959
ENSE00002170966	125040590	125041489
ENSE00003475566	125038921	125039069
ENSE00003650071	125038431	125038604
ENSE00003844056	124954202	124954370

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 93.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.8583 / max 78.0778, expressed in 1401 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117424	2.5599	937
117423	1.6334	916
117425	0.5905	339
117422	0.0745	17

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	93.24	gold quality
secondary oocyte	CL:0000655	92.66	gold quality
sperm	CL:0000019	86.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.09	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.44	gold quality
male germ cell	CL:0000015	84.33	gold quality
left testis	UBERON:0004533	80.40	gold quality
right testis	UBERON:0004534	80.27	gold quality
testis	UBERON:0000473	79.58	gold quality
ganglionic eminence	UBERON:0004023	74.34	gold quality
buccal mucosa cell	CL:0002336	73.60	gold quality
ventricular zone	UBERON:0003053	73.45	gold quality
calcaneal tendon	UBERON:0003701	72.94	gold quality
minor salivary gland	UBERON:0001830	70.03	gold quality
bone marrow	UBERON:0002371	69.80	gold quality
skin of abdomen	UBERON:0001416	67.80	gold quality
stromal cell of endometrium	CL:0002255	67.78	gold quality
saliva-secreting gland	UBERON:0001044	67.73	gold quality
skin of leg	UBERON:0001511	67.61	gold quality
right uterine tube	UBERON:0001302	66.75	gold quality
zone of skin	UBERON:0000014	66.72	gold quality
mouth mucosa	UBERON:0003729	66.70	gold quality
granulocyte	CL:0000094	66.38	gold quality
trabecular bone tissue	UBERON:0002483	66.23	silver quality
tibia	UBERON:0000979	65.76	silver quality
adrenal tissue	UBERON:0018303	65.50	gold quality
bronchial epithelial cell	CL:0002328	64.90	silver quality
leukocyte	CL:0000738	64.48	gold quality
hair follicle	UBERON:0002073	64.41	gold quality
embryo	UBERON:0000922	64.17	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-8060	no	70.03
E-ANND-3	no	4.86

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

51 targeting CCDC15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-4328	99.57	71.06	4094

Literature-anchored findings (GeneRIF, showing 1)

• CCDC15 localizes to the centriole inner scaffold and controls centriole length and integrity. (PMID:37934472)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc15	ENSDARG00000067517
mus_musculus	Ccdc15	ENSMUSG00000034303
rattus_norvegicus	Slc37a2	ENSRNOG00000039390

Protein

Protein identifiers

Coiled-coil domain-containing protein 15 — Q0P6D6 (reviewed: Q0P6D6)

All UniProt accessions (2): Q0P6D6, E9PKB1

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in primary cilium assembly, maintenance, and length regulation. Interacts with centriole inner scaffold proteins to promote proper centriole size and integrity and assembly of functional cilia. Required for the recruitment of both the inner scaffold protein POC1B and the distal SFI1/CETN2 complex to centrioles.

Subunit / interactions. Interacts with POC5, POC1B, CETN2 and FAM161A.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole. Centriolar satellite.

RefSeq proteins (1): NP_079280* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR037693	CCDC15	Family

UniProt features (10 total): coiled-coil region 4, sequence variant 3, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q0P6D6-F1	50.02	0.09

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 91 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, MULLIGHAN_NPM1_SIGNATURE_3_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_REGULATION_OF_CENTRIOLE_REPLICATION, GOBP_CENTRIOLE_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, CATTTCA_MIR203, WANG_LMO4_TARGETS_DN, GOBP_CILIUM_ORGANIZATION, GOBP_REGULATION_OF_CELL_CYCLE

GO Biological Process (3): cilium assembly (GO:0060271), positive regulation of centriole elongation (GO:1903724), cell projection organization (GO:0030030)

GO Molecular Function (0):

GO Cellular Component (5): centrosome (GO:0005813), centriole (GO:0005814), centriolar satellite (GO:0034451), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
microtubule organizing center	2
intracellular membraneless organelle	2
cellular anatomical structure	2
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
positive regulation of centriole replication	1
centriole elongation	1
regulation of centriole elongation	1
cellular component organization	1
centriole	1
centrosome	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

314 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC15	A6NDT3	A6NDT3	571
CCDC15	SH2D4A	Q9H788	557
CCDC15	RELL2	Q8NC24	528
CCDC15	SCML2	Q9UQR0	495
CCDC15	CCDC102B	Q68D86	486
CCDC15	CCDC106	Q9BWC9	453
CCDC15	CCDC154	A6NI56	446
CCDC15	SPATC1	Q76KD6	446
CCDC15	DNASE1L2	Q92874	436
CCDC15	IFI30	P13284	427
CCDC15	ZNF227	Q86WZ6	418
CCDC15	SYCE2	Q6PIF2	399
CCDC15	NEDD4	P46934	392
CCDC15	SLC24A3	Q9HC58	390
CCDC15	ZGRF1	Q86YA3	374

IntAct

5 interactions, top by confidence:

A	B	Type	Score
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
MEF2A	REV3L	psi-mi:“MI:0914”(association)	0.350
TIAM1	CCDC15	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): CCDC15 (Proximity Label-MS), CCDC15 (Proximity Label-MS), CCDC15 (Affinity Capture-MS), CCDC15 (Affinity Capture-MS), CCDC15 (Affinity Capture-RNA), CCDC15 (Affinity Capture-MS), CCDC15 (Proximity Label-MS), CCDC15 (Proximity Label-MS), CCDC15 (Affinity Capture-MS), CCDC15 (Two-hybrid), CCDC15 (Cross-Linking-MS (XL-MS)), CCDC15 (Cross-Linking-MS (XL-MS)), CCDC15 (Affinity Capture-RNA), CCDC15 (Proximity Label-MS), CCDC15 (Proximity Label-MS)

ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0J9YY54, A0A0U1RQI7, A6NJ88, A6QL64, B4DH59, D3ZVV1, E9Q6E9, F1LWT0, O04492, O88799, P0DKJ7, P0DKJ8, P0DKL2, P0DPF3, P18583, P53353, Q08AG5, Q0P6D6, Q2EG98, Q3BBV2, Q4ZJZ1, Q5HY64, Q5JPF3, Q5QGU6, Q5TAG4, Q5TI25, Q5XHX6, Q6P3W6, Q6P902, Q6XPR3, Q6ZQX7, Q86T75, Q86VE3, Q86VQ3, Q8N2N9, Q8N660, Q8N693, Q96EQ9

Diamond homologs: Q0P6D6, Q8C9M2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

157 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	131
Likely benign	9
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
395037	GRCh37/hg19 11q24.2(chr11:124254553-125315622)x1	Pathogenic
563884	GRCh37/hg19 11q23.3-25(chr11:116681007-134938470)x3	Pathogenic
625808	GRCh37/hg19 11q23.3-25(chr11:116700253-134904063)	Pathogenic

SpliceAI

2484 predictions. Top by Δscore:

Variant	Effect	Δscore
11:124954844:GC:G	donor_gain	1.0000
11:124959105:A:AG	acceptor_gain	1.0000
11:124959106:T:G	acceptor_gain	1.0000
11:124959111:A:AG	acceptor_gain	1.0000
11:124959112:A:G	acceptor_gain	1.0000
11:124959112:AAG:A	acceptor_loss	1.0000
11:124959113:A:G	acceptor_gain	1.0000
11:124959114:G:GG	acceptor_gain	1.0000
11:124959114:G:GT	acceptor_loss	1.0000
11:124959261:AAGA:A	donor_gain	1.0000
11:124959262:AGAG:A	donor_loss	1.0000
11:124959263:GA:G	donor_gain	1.0000
11:124959264:AGT:A	donor_loss	1.0000
11:124959265:G:GG	donor_gain	1.0000
11:124959266:TAAG:T	donor_loss	1.0000
11:124959999:AGGCT:A	donor_gain	1.0000
11:124960000:GGCTG:G	donor_gain	1.0000
11:124960001:GCT:G	donor_gain	1.0000
11:124960002:CT:C	donor_gain	1.0000
11:124960004:G:GG	donor_gain	1.0000
11:124960005:TAAG:T	donor_loss	1.0000
11:124960008:G:GG	donor_gain	1.0000
11:124986737:TTTA:T	acceptor_loss	1.0000
11:124986739:TAG:T	acceptor_loss	1.0000
11:124986740:A:AG	acceptor_gain	1.0000
11:124986740:AG:A	acceptor_gain	1.0000
11:124986741:G:A	acceptor_gain	1.0000
11:124986741:G:GG	acceptor_gain	1.0000
11:124986741:GGA:G	acceptor_gain	1.0000
11:124986741:GGAA:G	acceptor_gain	1.0000

AlphaMissense

6330 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:125039035:T:G	C900W	0.990
11:125038938:G:C	R868P	0.989
11:125039033:T:C	C900R	0.989
11:125039045:T:C	C904R	0.989
11:125039047:T:G	C904W	0.989
11:125039051:T:C	F906L	0.989
11:125039053:C:A	F906L	0.989
11:125039053:C:G	F906L	0.989
11:125005137:G:C	R779P	0.988
11:125038991:T:C	C886R	0.988
11:124959206:G:C	R90P	0.987
11:125038993:C:G	C886W	0.987
11:125039034:G:A	C900Y	0.986
11:125038997:T:C	C888R	0.985
11:125039033:T:A	C900S	0.985
11:125039034:G:C	C900S	0.985
11:124959184:T:C	F83L	0.984
11:124959186:T:A	F83L	0.984
11:124959186:T:G	F83L	0.984
11:125038931:G:C	A866P	0.984
11:125038998:G:A	C888Y	0.984
11:125039009:T:C	F892L	0.984
11:125039011:T:A	F892L	0.984
11:125039011:T:G	F892L	0.984
11:125039012:T:A	W893R	0.983
11:125039012:T:C	W893R	0.983
11:125039052:T:C	F906S	0.983
11:125040605:T:C	L917P	0.983
11:125038999:T:G	C888W	0.982
11:125040592:T:G	Y913D	0.982

dbSNP variants (sampled 300 via entrez): RS1000034363 (11:124970186 C>G), RS1000038016 (11:125009047 C>T), RS1000047309 (11:125016009 A>G), RS1000109721 (11:125009286 A>G), RS1000123018 (11:124981193 G>A), RS1000127143 (11:124983039 G>T), RS1000159031 (11:125039851 A>G), RS1000219609 (11:124980805 T>A), RS1000236668 (11:125028233 G>A), RS1000322046 (11:125002352 C>T), RS1000425148 (11:124970473 A>G), RS1000514880 (11:124960747 A>G), RS1000566443 (11:124974641 G>T), RS1000567330 (11:125027999 C>T), RS1000575980 (11:125019214 C>T)

Disease associations

OMIM: gene MIM:621146 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002282_21	Parasitemia in Tripanosoma cruzi seropositivity	1.000000e-07
GCST002861_2	Breast cancer (survival)	1.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005528	parasitemia measurement
EFO:0000714	survival time

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	4
Cyclosporine	decreases expression	3
Tetrachlorodibenzodioxin	decreases expression	2
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
bisphenol A	decreases expression	1
trichostatin A	increases expression	1
potassium chromate(VI)	decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
incobotulinumtoxinA	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	increases expression	1
Leflunomide	decreases expression	1
Azathioprine	decreases expression	1
Benzo(a)pyrene	increases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	increases expression	1
Cytarabine	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Dihydrotestosterone	increases expression	1
Testosterone	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1

Clinical trials (associated diseases)

213 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder